Page 149 - Drug Class Review

diarrhea, dizziness, and agitation; at 8 mg/d, the differences between GAL and placebo were not significant;
Drug Effectiveness Review Project
>1 indicates greater adverse events for GAL; adverse events recorded (in order of magnitude of the greatest
Refers to Cochrane Dementia and Cognitive Improvement Group search strategy; trials were selected from
GAL (P = NR); at 32 mg/d nausea, vomiting, dizziness, weight loss, anorexia, abdominal pain, tremor, and
nausea, vomiting, dizziness, weight loss, anorexia, tremor and headache were statistically more frequent in
frequently in GAL versus placebo; the proportion of subjects with those adverse events was analyzed; OR
at 16 mg/d nausea, vomiting, and diarrhea were statistically more frequent in GAL (P = NR); at 24 mg/d
Three 6-month studies reported those adverse events appearing at least 5% of the time occurred more
effect size by daily dose): tremor, anorexia, vomiting, nausea, weight loss, headache, abdominal pain
the Trial-based Specialized Register of the Cochrane Dementia and Cognitive Improvement Group,
headache were statistically more frequent in GAL
CCTR/Central, EMBASE) containing records from a number of published and unpublished electronic databases (e.g., MEDLINE, Cochrane Collaboration guidelines (Mulrow 1997) Page 105 of 205

Good

Final Report Update 1 Authors: Olin & Schneider, Loy & Schneider Year: 2004, 2005 ADVERSE EVENTS: COMPREHENSIVE LITERATURE SEARCH STRATEGY: STANDARD METHOD OF APPRAISAL OF STUDIES: QUALITY RATING: Alzheimer's Drugs